MétaCan
Menu
Back to cohort
Record W3134378458 · doi:10.1186/s13063-021-05235-3

Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial

2021· article· en· W3134378458 on OpenAlexafffund
Philippe Bégin, Jeannie Callum, Nancy M. Heddle, Richard J. Cook, Michelle P. Zeller, Alan Tinmouth, Dean Fergusson, Melissa M. Cushing, Marshall J. Glesby, Michaël Chassé, Dana V. Devine, Nancy Robitalle, Renée Bazin, Nadine Shehata, Andrés Finzi, Allison McGeer, Damon C. Scales, Lisa Schwartz, Alexis F. Turgeon, Ryan Zarychanski, Nick Daneman, Richard Carl, Luiz Amorim, Caroline Gabe, Martin Ellis, Bruce S. Sachais, Kent Cadogan Loftsgard, Erin Jamula, Julie Carruthers, Joanne Duncan, Kayla J. Lucier, Na Li, Yang Liu, Chantal Armali, Amie Kron, Dimpy Modi, Marie‐Christine Auclair, Sabrina Cerro, Meda Avram, Donald M. Arnold

Bibliographic record

VenueTrials · 2021
Typearticle
Languageen
FieldMedicine
TopicCOVID-19 Clinical Research Studies
Canadian institutionsUniversity of ManitobaImpactSinai Health SystemPublic Health OntarioUniversity of CalgaryMount Sinai HospitalHéma-QuébecUniversity of British ColumbiaUniversité LavalCentre Hospitalier de l’Université de MontréalMcMaster University Medical CentreHealth Sciences CentreOttawa HospitalUniversity of OttawaSunnybrook Health Science CentreCanadian Blood ServicesUniversity of TorontoUniversité de MontréalUniversity of WaterlooMcMaster UniversityHamilton Health SciencesCentre Hospitalier Universitaire Sainte-Justine
FundersGovernment of SaskatchewanUniversity Hospital FoundationWeill Cornell Medical CollegeMcMaster UniversityCanadian Institutes of Health ResearchHamilton Health Sciences
KeywordsMedicineRandomized controlled trialIntubationPneumoniaRandomizationPlaceboInternal medicineIntensive care medicineEmergency medicineAnesthesia

Abstract

fetched live from OpenAlex

BACKGROUND: Convalescent plasma has been used for numerous viral diseases including influenza, severe acute respiratory syndrome, Middle East respiratory syndrome and Ebola virus; however, evidence to support its use is weak. SARS-CoV-2 is a novel coronavirus responsible for the 2019 global pandemic of COVID-19 community acquired pneumonia. We have undertaken a randomized controlled trial to assess the efficacy and safety of COVID-19 convalescent plasma (CCP) in patients with SARS-CoV-2 infection. METHODS: CONCOR-1 is an open-label, multicentre, randomized trial. Inclusion criteria include the following: patients > 16 years, admitted to hospital with COVID-19 infection, receiving supplemental oxygen for respiratory complications of COVID-19, and availability of blood group compatible CCP. Exclusion criteria are : onset of respiratory symptoms more than 12 days prior to randomization, intubated or imminent plan for intubation, and previous severe reactions to plasma. Consenting patients are randomized 2:1 to receive either approximately 500 mL of CCP or standard of care. CCP is collected from donors who have recovered from COVID-19 and who have detectable anti-SARS-CoV-2 antibodies quantified serologically. The primary outcome is intubation or death at day 30. Secondary outcomes include ventilator-free days, length of stay in intensive care or hospital, transfusion reactions, serious adverse events, and reduction in SARS-CoV-2 viral load. Exploratory analyses include patients who received CCP containing high titre antibodies. A sample size of 1200 patients gives 80% power to detect a 25% relative risk reduction assuming a 30% baseline risk of intubation or death at 30 days (two-sided test; α = 0.05). An interim analysis and sample size re-estimation will be done by an unblinded independent biostatistician after primary outcome data are available for 50% of the target recruitment (n = 600). DISCUSSION: This trial will determine whether CCP will reduce intubation or death non-intubated adults with COVID-19. The trial will also provide information on the role of and thresholds for SARS-CoV-2 antibody titres and neutralization assays for donor qualification. TRIAL REGISTRATION: Clinicaltrials.gov NCT04348656 . Registered on 16 April 2020.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.022
metaresearch head score (Gemma)0.017
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Protocol · Consensus signal: Protocol
Teacher disagreement score0.061
Threshold uncertainty score0.203

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0220.017
Meta-epidemiology (narrow)0.0080.003
Meta-epidemiology (broad)0.0100.004
Bibliometrics0.0020.002
Science and technology studies0.0030.004
Scholarly communication0.0040.005
Open science0.0040.002
Research integrity0.0080.008
Insufficient payload (model declined to judge)0.0610.012

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.447
GPT teacher head0.611
Teacher spread0.164 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreProtocol

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations28
Published2021
Admission routes2
Has abstractyes

Explore more

Same venueTrialsSame topicCOVID-19 Clinical Research StudiesFrench-language works237,207